This trial is evaluating whether TQJ230 will improve 2 primary outcomes and 3 secondary outcomes in patients with Cardiovascular Disease and Lipoprotein(a). Measurement will happen over the course of approximately 4 years.
This trial requires 8323 total participants across 2 different treatment groups
This trial involves 2 different treatments. TQJ230 is the primary treatment being studied. Participants will all receive the same treatment. Some patients will receive a placebo treatment. The treatments being tested are in Phase 3 and have had some early promising results.
"Current research and evidence do not support the notion that cardiovascular diseases can be cured. With appropriate treatment, however, it is possible to diminish or stop the course of the diseases, but with very low rates of cure." - Anonymous Online Contributor
"The data obtained point to an urgent need for campaigns aiming to warn citizens of the cardiovascular disease. The high percentage of smokers of the sample, the overconsumption of alcohol and coffee and the inadequate physical activity are also serious points of need for the creation of future strategies of the public health." - Anonymous Online Contributor
"The common CVDs were CVDs, including atherosclerosis and atherosclerotic syndrome, coronary heart disease, arrhythmia, cerebrovascular disease, hypertension, and chronic kidney disease. The CVDs may cause morbidity, physical, psychological, and economic burden to society. Furthermore, CVDs are the predominant cause of mortality on both national and international level. Prevention and intervention are necessary to reduce these diseases and associated morbidity and mortality." - Anonymous Online Contributor
"The primary causes of cardiovascular diseases are: a) physical inactivity; b) increased body weight; c) diabetes mellitus and obesity d) tobacco use; e) chronic infections; f) chronic stress; and g) environmental factors." - Anonymous Online Contributor
"There is not a single treatment of choice for CVDs. Treatment focuses on prevention and primary prevention, where effective treatments are often first-line therapies. New and more advanced medical therapies are being studied. Some treatments have significant side effects, so caution must be taken when prescribing or prescribing medications for these treatments." - Anonymous Online Contributor
"There have been no other trials to test tqj230 in CHF or atrial fibrillation, and therefore it is not clear whether or not tqj230 can be safely administered for these uses. There is no compelling evidence to support a recommendation for or against treatment for tqj230 for CHF or atrial fibrillation. A larger study is required." - Anonymous Online Contributor
"In last decade, there was a boom in the use of vascular surgical procedures. It is also evident that the mortality rate was quite high for such procedures." - Anonymous Online Contributor
"For some of them, it can be extremely serious. In addition, for others, the severity is often not known. Data from a recent study in this paper could be useful for clinicians who wish to discuss the severity of CV diseases with patients at a consultation." - Anonymous Online Contributor
"Even if there were differences in CV susceptibility at younger ages, which does not appear to be the case in Denmark, they disappeared when age was regarded as a covariate in multivariable models. Furthermore, we found a stronger contribution from the familial component in women, when age was regarded as a covariate. This indicates that familial factors are more important for CV diseases in females, and that they are less relevant in men." - Anonymous Online Contributor
"There is no evidence that tqj230 is more effective when given in combination with other treatments as a maintenance treatment vs. monotherapy. In this cohort, tqj230 was more effective as maintenance therapy than as an add-on treatment in adults with IBS." - Anonymous Online Contributor